1 December 2022 - The December 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The December issue of the Schedule includes a number of major new/revised listings:

• Bevacizumab (Abevmy) - new biosimilar medicine
• Evolocumab (Repatha) - restriction change
• Leuprorelin acetate (Eligard 6 month) - new indication
• Lorlatinib (Lorviqua) - new indication
• Natalizumab (Tysabri) - restriction change
• Pegcetacoplan (Empaveli) - new medicine
• Pembrolizumab (Keytruda) - restriction change
• Vericiguat (Verquvo) - new medicine

Read summary of PBS changes